Ftse Mib
34.374,77
0,55%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.907,86
0,01%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ SciSparc Ltd (SPRC) SciSparc Ltd (SPRC) Notizie

SPRC

SciSparc (SPRC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SPRC
DataOraFonteTitoloSimboloCompagnia
31/12/202422:16Edgar (US Regulatory)Form F-4/A - Registration of securities, foreign private issuers, business combinations: [Amend]NASDAQ:SPRCSciSparc Ltd
31/12/202422:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
31/12/202415:24GlobeNewswire Inc.SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
26/12/202422:06Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:SPRCSciSparc Ltd
26/12/202412:46GlobeNewswire Inc.SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct ImportationNASDAQ:SPRCSciSparc Ltd
16/12/202413:40GlobeNewswire Inc.SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded CompanyNASDAQ:SPRCSciSparc Ltd
30/09/202415:25GlobeNewswire Inc.SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome TreatmentNASDAQ:SPRCSciSparc Ltd
26/09/202415:05GlobeNewswire Inc.SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareXNASDAQ:SPRCSciSparc Ltd
23/09/202414:17GlobeNewswire Inc.SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome TreatmentNASDAQ:SPRCSciSparc Ltd
18/09/202422:09GlobeNewswire Inc.SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome TreatmentNASDAQ:SPRCSciSparc Ltd
16/09/202422:06GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination TherapyNASDAQ:SPRCSciSparc Ltd
11/09/202413:40GlobeNewswire Inc.SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle ManufacturerNASDAQ:SPRCSciSparc Ltd
06/09/202413:55GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentNASDAQ:SPRCSciSparc Ltd
06/09/202413:55GlobeNewswire Inc.Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentNASDAQ:SPRCSciSparc Ltd
06/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SPRCSciSparc Ltd
29/08/202422:25GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based CombinationNASDAQ:SPRCSciSparc Ltd
28/08/202422:05Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:SPRCSciSparc Ltd
28/08/202414:55GlobeNewswire Inc.SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 MillionNASDAQ:SPRCSciSparc Ltd
23/08/202422:09GlobeNewswire Inc.SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette SyndromeNASDAQ:SPRCSciSparc Ltd
22/08/202414:12GlobeNewswire Inc.SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory BoardNASDAQ:SPRCSciSparc Ltd
19/08/202422:11GlobeNewswire Inc.SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 TreatmentNASDAQ:SPRCSciSparc Ltd
16/08/202422:30GlobeNewswire Inc.SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 millionNASDAQ:SPRCSciSparc Ltd
14/08/202422:53GlobeNewswire Inc.SciSparc Updates Regarding the Status of the AutoMax MergerNASDAQ:SPRCSciSparc Ltd
06/08/202414:57GlobeNewswire Inc.SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss DrugNASDAQ:SPRCSciSparc Ltd
17/07/202413:07GlobeNewswire Inc.SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 millionNASDAQ:SPRCSciSparc Ltd
16/07/202417:55GlobeNewswire Inc.SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:SPRCSciSparc Ltd
16/07/202412:03GlobeNewswire Inc.SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight LossNASDAQ:SPRCSciSparc Ltd
08/07/202414:30GlobeNewswire Inc.SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded CompanyNASDAQ:SPRCSciSparc Ltd
17/06/202422:05Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SPRCSciSparc Ltd
31/05/202413:17GlobeNewswire Inc.SciSparc Secures Strategic Advantage with Grant of European PatentNASDAQ:SPRCSciSparc Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SPRC

La tua Cronologia

NASDAQ
ABNOYXX
Citigroup Global Markets...
ASX
RPG
Raptis
TG
A19HNY
Capex
HITB
HPCBTC
Happycoin
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network